The fourth hurdle as controlling instrument for expenditure on medication?

European Journal of Health Economics

Volumn 4, Issue 1, 2003, Pages 1-5

  Kulp, Werner ^a   Greiner, W ^b   Von der Schulenburg, J M ^b  

^a LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUSTRALIA; CANADA; COST; DECISION MAKING; DRUG INDICATION; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; FINANCIAL MANAGEMENT; FINLAND; HEALTH CARE COST; HUMAN; MEDICAL SERVICE; MONEY; NETHERLANDS; ORGANIZATION; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; QUALITY CONTROL; REGULATORY MECHANISM; SOCIAL ASPECT;

EID: 0037270120     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-003-0166-5     Document Type: Editorial

References (25)

1. Burke A. No Cash to Implement NICE Health Authorities MPs Told, BMJ 2002a; 324:191
2. Burke A. NICE May Fail to Stop,Post-code Prescribing" MPs Told, BMJ 2002b; 324:191
3. Commonwealth of Australia, Pharmaceutical Benefits Pricing Authority 2001.Annual Report 2001: 8 (http://www.health.gov.au/pbs/pricing/pbparpt.htm) (1S.02.2003)
4. Commonwealth of Australia, Department of the Parliament Library 2002. The Pharmceutical Benefit Scheme: Options of Cost Control 2002 (http://www.aph.gov.au/library/pubs/ClB/2001-O2/O2cib12.htm) (15.02.2003)
5. DiMasi JA, Caglarcan E, Wood-Armany M. Emerging Role of Pharmacoeconomics in Research and Development Process; Pharmacoeconomics 2001; 19(7):753-66
6. Drummond M. The Emerging Government Requirement for Economic Evaluation of Pharmaceuticals, Pharmacoeconomics 1994; 6 (Suppl. 1) 42-50
7. Drummond M. Time for a Change in Drug Licensing Requirements? HEPAC 2002; 2: 137-138
8. Federal Statistical Office Germany (Statistisches Bundesamt). Neue Gesundheitsausgabenrechnung: Ausgaben nach Leistungsarten, Statistisches Bundesamt 2002 (http://www.destatis.de/basis/d/gesu/gesutab4.htm) (15.02.2003)
9. Hart D. Health Technology Assessment (HTA) und gesundheitsrechtliche Regulierung,MedR 2001; 1: 1-8
10. Hughes DA, Walley. Economic Evaluations During Early (Phase II) Drug Development, Pharmacoeconomics 2001; 19 (11):1069-1077
11. IMS Health, Drug Monitor: 12 Month to May 2002 (http://open.imshealth.com/download/may2002.pdf) (1S.02.2003)
12. Kanavos P, Trueman P, Bosilevac. Can Economic Evaluation Guidelines Improve Efficiency in Resource Allocation? The Cases of Portugal, the Netherlands, Finland and the UK, LSE Health, London School of Economics & Political Science 2000 (http://www.lse.ac.uk/Depts/Isehsc/papers/Discussion_Papers/dpl 5.final.pdf) (15.02.2003)
13. Kmittowicz M. NHS must provide Bupropion for Smokers to quit, NICE says. BMJ 2002; 324: 937
14. Langley PC,The November 1995 Revised Australian Guidelines for the Evonomic Evaluation of Pharmaceuticals. Pharmacoeconomics 1996;4:341-352
15. Mauskopf J,Schulman K, Bell L,Glick H.A. Strategy for Collecting Pharmacoeconmic Data During Phase II/Ill Clinical Trials in Mallarkey G (edit.) Economic Evaluation in Healthcare
16. Mayor 5.NICE estimates that its Recommendations have cost the NHS £ 575m. BMJ 2002; 325: 924
17. NHS Alliance. Deciscions by NICE not preventing Postcode Rationing, NHS Alliance 2001, (http://www.nhsalliance.org/press/2001/15FebO1.htm) (15.02.2003)
18. Nuijten MJC, Berto P, Berdeaux G, Hutton J, Fricke FU,Villar FA.Trends in Decision-making Process for Pharmaceuticals in Western European Countries, HEPAC 2002; 2: 162-169
19. Federal Statistical Office Germany (Statistisches Bundesamt). Neue Gesundheitsausgabenrechnung: Ausgaben nach Leistungsarten, Statistisches Bundesamt 2002 (http://www.destatis.de/basis/d/gesu/gesutab4.htm) (15.02.2003)
20. Schulenburg JM von der, Scḧffski O. Transformation des Gesundheitswesens im Spannungsfeld zwischen Kostendämpfung und Freiheit: Eine ökonomische Analyse des veränderten Überweisungs- und Einweisungsverhaltens nach den Arzneimittelregulierungen des GSG, in: P.Oberender (Hrsg.), Probleme der Transformation im Gesundheitswesen: Nomos Verlag Baden-Baden 1994, 45-81
21. Schulenburg JM Graf von der, Greiner W. Gesundheitsökonomik, Mohr Siebeck Tübingen 2000a:140
22. Schulenburg JM Graf von der, Hoffmann C. Review of European Guidelines for Economic Evaluation of Medical Technologies and Pharmaceuticals, HEPAC 2000b; 1: 2-8
23. Schwabe U (2002) Überblick über die Arzneiverordnungen im Jahre 2001. In: Schwabe U, Paffrath D (edit) Medication Prescription Report (Arzneiverordnungsreport) 2002, Springer Berlin, pp1-22
24. Smith R. BMJ 2000; 321: 1363-1364
25. Volmer T. Die Rolle der Gesundheitsökonomie bei der Bewertung von Arzneimittel aus der Sicht der pharmazeutischen Industrie,in Michaelis W (edit.) Der Preis der Gesundheit, Ecomed Verlagsgesellschaft Landsberg 2001:46-60